Research programme: amniotic stem cell therapies - Creative Medical Technology Holdings
Latest Information Update: 19 Dec 2016
At a glance
- Originator Creative Medical Technology Holdings
- Class Cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Primary ovarian insufficiency; Stroke